IO Biotech Provides Business Update
NEW YORK, Jan. 09, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® vaccine platform, today provided a business update.
Related news for (IOBT)
- Breaking News: MoBot’s Latest Update as of 10/21/25 03:00 PM
- From Spider Silk to Skin Science: Innovation Threads Through Wall Street
- IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025
- Breaking News: MoBot’s Latest Update as of 10/20/25 07:00 AM
- 24/7 Market News Snapshot 20 October, 2025 – IO Biotech, Inc. Common Stock (NASDAQ:IOBT)
